Hexaminolevulinate blue light cystoscopy: A review of its use in the diagnosis of bladder cancer

Molecular Diagnosis and Therapy

Volumn 18, Issue 1, 2014, Pages 105-116

  Yang, Lily P H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; MITOMYCIN;

BLADDER CANCER; BLADDER FILLING; BLUE LIGHT; BLUE LIGHT CYSTOSCOPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CYSTOSCOPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; URINARY FREQUENCY; WHITE LIGHT;

AMINOLEVULINIC ACID; CLINICAL TRIALS AS TOPIC; CYSTOSCOPY; HUMANS; META-ANALYSIS AS TOPIC; MICROSCOPY, FLUORESCENCE; NEOPLASM RECURRENCE, LOCAL; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84893283322     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0068-x     Document Type: Review

References (50)

1. Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol. 2010;57(4):607-14.
2. US National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer (version 1.2013). 19 Nov 2012. http://www.nccn.org/professionals/physician-gls/pdf/bladder.pdf. Accessed 28 May 2013.
3. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295-300.
4. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523-31.
5. International Consortium for Urologic Diseases - European Association of Urology, Soloway M, Khoury S. International Consultation on Urologic Diseases: bladder cancer. 2nd ed. 2012. http://www.icud.info/PDFs/ Bladder%20Cancer%20Second%20Edition%202012.pdf. Accessed 27 Sep 2013.
6. European Association of Urology. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Mar 2013. http://www.uroweb.org/gls/pdf/05-TaT1- Bladder-Cancer-LR.pdf. Accessed 28 May 2013.
7. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158-67.
8. Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63(1):4-15.
9. Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol. 2012;188(2):361-8.
10. Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110(5):2795-838.
11. Wachowska M, Muchowicz A, Firczuk M, et al. Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules. 2011;16(5):4140-64.
12. Bordier B, Mazerolles C, Malavaud B. Photodynamic diagnosis in non-muscle-invasive bladder cancer. Eur Urol Suppl. 2010;9(3):411-8.
13. Photocure ASA. Cysview (hexaminolevulinate HCl): US prescribing information. Nov 2011. http://www.cysview.com/wp-content/uploads/2013/08/ Prescribing-Information.pdf. Accessed 3 Oct 2013.
14. Ipsen Ltd. Hexvix 85 mg: summary of product characteristics. 15 Apr 2013. http://www.medicines.org.uk/emc/medicine/27028/SPC/Hexvix+85mg/. Accessed 23 May 2013.
15. van den Berg NS, van Leeuwen FW, van der Poel HG. Fluorescence guidance in urologic surgery. Curr Opin Urol. 2012;22(2):109-20.
16. Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999;80(1-2):185-93.
17. Rink M, Babjuk M, Catto JW, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624-38.
18. Frampton JE, Plosker GL. Hexyl aminolevulinate: in the detection of bladder cancer. Drugs. 2006;66(4):571-8.
19. Marti A, Lange N, van den Bergh H, et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol. 1999;162(2):546-52.
20. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 2003;170(2 Pt 1):428-32.
21. Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol. 2006;46(4):456-60.
22. Collaud S, Jichlinski P, Marti A, et al. An open pharmacokinetic study of hexylaminolevulinate-induced photodiagnosis after intravesical administration. Drugs R D. 2006;7(3):173-86.
23. Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57(8):1481-6.
24. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68-73.
25. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178(1):62-7.
26. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862-6.
27. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135-8.
28. Burgués JP, Conde G, Oliva J, et al. Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group. Actas Urol Esp. 2011;35(8):439-45.
29. Geavlete B, Jecu M, Multescu R, et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer: re-TURBT recurrence rates in a prospective, randomized study. Urology. 2010;76(3):664-9.
30. Geavlete B, Multescu R, Georgescu D, et al. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int. 2012;109(4):549-56.
31. Hermann GG, Mogensen K, Carlsson S, et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011;108(8 Pt 2):E297-303.
32. Karaolides T, Skolarikos A, Bourdoumis A, et al. Hexaminolevulinate- induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology. 2012;80(2):354-9.
33. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907-13.
34. Lerner SP, Liu H, Wu M-F, et al. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol. 2012;30(3):285-9.
35. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846-54.
36. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer: a multicenter study. J Urol. 2003;170(1):226-9.
37. Drǎgoescu O, Tomescu P, Panus A, et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol. 2011;52(1):123-7.
38. Ray ER, Chatterton K, Thomas K, et al. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. J Endourol. 2009;23(6):983-8.
39. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188(1):58-62.
40. Bennison C, Tempest F, Marteau A, et al. Benefit of hexaminolevulinate (HAL) technology for patients and healthcare systems in non-muscle invasive bladder cancer (NMIBC) in Italy. 10th Health Technology Assessment International; 17-19 Jun 2013; Seoul.
41. Garfield SS, Gavaghan MB, Armstrong SO, et al. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013;20(2):6682-9.
42. Malmström P-U, Hedelin H, Thomas YK, et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol. 2009;43(3):192-8.
43. Colapaoli L, Thorsen J, Nopp A, et al. A case of anaphylactic shock possibly caused by intravesical Hexvix. Acta Anaesthesiol Scand. 2006;50(9):1165-7.
44. Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36-44.
45. Gravas S, Efstathiou K, Zachos I, et al. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol. 2012;19(3):6269-73.
46. Roy A, Pal P, Arya M, et al. Photodynamic diagnostic cystoscopy. BJU Int. 2012;110(6):914-7.
47. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 2010;105(6):789-94.
48. Burger M, Stief CG, Zaak D, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009;74(6):1282-6.
49. Li K, Lin T, Fan X, et al. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. In J Urol. 2013;20(6):602-9.
50. Zheng C, Lv Y, Zhong Q, et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680-7.